Kura Oncology (KURA) Total Non-Current Liabilities (2014 - 2026)

Kura Oncology (KURA) has 13 years of Total Non-Current Liabilities data on file, last reported at $541.2 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $541.2 million, up 43.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $541.2 million (up 43.48% YoY), and the FY2025 annual result was $561.1 million, up 62.76% from the prior year.
• Total Non-Current Liabilities slipped to $541.2 million in Q1 2026 per KURA's latest filing, from $561.1 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $561.1 million in Q4 2025 and troughed at $21.5 million in Q2 2022.
• A 5-year average of $177.5 million and a median of $47.9 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities plunged 35.45% in 2022, then surged 687.96% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $35.8 million in 2022, then jumped by 42.49% to $51.0 million in 2023, then surged by 576.5% to $344.7 million in 2024, then surged by 62.76% to $561.1 million in 2025, then fell by 3.53% to $541.2 million in 2026.
• Business Quant data shows KURA's Total Non-Current Liabilities at $541.2 million in Q1 2026, $561.1 million in Q4 2025, and $403.9 million in Q3 2025.